05:01 PM EST, 02/27/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) reported a Q4 loss late Thursday of $0.85 per diluted share, narrowing from a loss of $2.06 a year ago.

Analysts polled by FactSet expected a loss of $0.54.

Revenue for the quarter that ended Dec. 31 was $213.2 million, down from $307.1 million a year earlier.

Analysts surveyed by FactSet expected $232.4 million.

The company said it expects full-year 2025 revenue of $600 million to $800 million. Analysts expected $735.2 million.

Shares of the company traded 5% lower in after-hours activity.